Speaking Engagements July 28, 2009

Navigating the Challenges of ANDA Disputes

The competition between brand name and generic pharmaceutical companies is fierce. Although the Hatch Waxman Act attempted a compromise between the opposing positions of Branded pharmaceuticals and Generics, ANDA litigation and, increasingly, settlements, continue to be a major component of strategy and development on both sides. The webcast's panel stakes out these competing positions.

Topics covered include:

  • Limitations on Settlement of Brand and Generic litigation
  • Relationship of Authorized Generics to Settlement of brand-generic litigation
  • At-risk launches in brand-generic litigation

Martin Voet
Former Senior VP Chief IP Counsel, Allergan, Inc.

Dominick Conde
Partner at Fitzpatrick Cella

Jay Deshmukh
Former Senior VP Global IP to Ranbaxy Labs

David Hashmall
Partner at Goodwin Procter

Steven Lee
Partner at Kenyon & Kenyon LLP

Edward W. Murray
Managing Counsel, Intellectual Property Litigation Merck & Co., Inc.